30 September 2021 : Clinical Research
Prospective Study on the Postoperative Use of Levosimendan After Conventional Heart Valve Replacement
Wei Sheng1ABCDEF*, Hui Qiao1ABCDEF, Zhaozhuo Niu1BCE, Tianyi Wang1BCE, Haoyou Li1CDE, Wenfeng Zhang1CDE, Jiantao Wu1CDE, Xiao Lv1ADEFDOI: 10.12659/MSM.932001
Med Sci Monit 2021; 27:e932001
Table 1 Comparison of preoperative and intraoperative clinical characteristics between the 2 groups.
| Characteristics | Levosimendan (n=93) | Control (n=92) | χ2 or t | P value |
|---|---|---|---|---|
| Age (year, mean±SD) | 66.5±7.4 | 65.9±7.2 | 0.559 | 0.577 |
| Sex (%) | 0.523 | 0.470 | ||
| Male | 59 (63.4) | 63 (68.5) | ||
| Female | 34 (36.6) | 29 (31.5) | ||
| Body mass index (Kg/m) | 22.8±3.1 | 23.5±3.2 | 1.511 | 0.133 |
| Hypertension (%) | 19 (20.4) | 17 (18.5) | 0.112 | 0.737 |
| Diabetes mellitus (%) | 8 (8.6) | 7 (7.6) | 0.061 | 0.805 |
| Chronic obstructive pulmonary disease (%) | 3 (3.2) | 2 (2.2) | 0.195 | 0.659 |
| Smoking history (%) | 51 (54.8) | 53 (57.6) | 0.144 | 0.704 |
| NYHA classification (%) | 0.253 | 0.615 | ||
| Class II~III | 72 (77.4) | 74 (80.4) | ||
| Class IV | 21 (22.6) | 18 (19.6) | ||
| Preoperative BNP (pg/mL, mean±SD) | 285.6±23.9 | 279.8±22.3 | 1.706 | 0.090 |
| Preoperative serum creatinine (μmol/L, SD) (umol/L, mean±SD) | 85.2±11.3 | 86.5±11.9 | 0.762 | 0.447 |
| Preoperative LVEF (%, mean±SD) | 52.1±2.4 | 51.6±2.1 | 1.507 | 0.133 |
| Operation (%) | 0.504 | >0.05 | ||
| MVR | 47 (50.5) | 42 (45.7) | ||
| AVR | 26 (28.0) | 27 (29.3) | ||
| DVR | 20 (21.5) | 23 (25.0) | ||
| CPB time | 115.2±10.5 | 117.4±11.5 | 1.359 | 0.176 |
| Cross-clamping time | 78.5±6.8 | 80.2±7.1 | 1.663 | 0.098 |
| NYHA – New York Heart Association; BNP – B-type natriuretic peptide; LVEF – left ventricular ejection fraction; MVR – mitral valve replacement; AVR – aortic valve replacement; DVR – double valve replacement; CPB – cardiopulmonary bypass. | ||||